Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport.

JACC. Basic to translational science·2025

Same author

Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.

JACC. Advances·2025

Same author

ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.

Journal of the American College of Cardiology·2024

Same author

Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.

European heart journal·2024

Same author

Case report: dyslipidaemia-dramatic increase in haemoglobin A1c following statin initiation.

European heart journal. Case reports·2024

Same author

CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.

Journal of the American Heart Association·2024

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Targeting lipoprotein (a): an evolving therapeutic landscape.

Lillian C Man¹, Erik Kelly, Danielle Duffy

¹Department of Medicine, Thomas Jefferson University Hospital, 1025 Walnut Street, Room 805, Philadelphia, PA, 19107, USA, Lillian.man@jefferson.edu.

Current Atherosclerosis Reports

|March 5, 2015

Summary

Lipoprotein (a) [Lp(a)] is a proven cardiovascular disease risk factor. This review explores emerging therapies aimed at reducing Lp(a) levels and mitigating associated cardiovascular risks.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Apr 16, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Genetics
Pharmacology

Background:

Lipoprotein (a) [Lp(a)] is an established, independent, and causal risk factor for cardiovascular disease.
Lp(a)]s proatherogenic, prothrombotic, and antifibrinolytic mechanisms contribute to increased cardiovascular risk.
Current guidelines recommend Lp(a) screening for high-risk individuals, but consensus on management is lacking.

Purpose of the Study:

This review focuses on pharmacologic approaches to reduce Lp(a) levels.
It examines both existing lipid-lowering drugs that also affect Lp(a) and novel therapies specifically targeting Lp(a).

Main Methods:

Review of current literature on pharmacologic interventions for Lp(a) reduction.
Analysis of therapies developed for other lipid-lowering indications and novel agents targeting Lp(a).

Main Results:

Numerous pharmacologic strategies are under investigation for their potential to lower Lp(a).
Some existing lipid-lowering drugs demonstrate Lp(a)-lowering effects.
Novel therapies specifically designed to target Lp(a) are in development, with varying efficacy.

Conclusions:

Targeted reduction of Lp(a) represents a promising therapeutic avenue for cardiovascular disease prevention.
The efficacy and role of these emerging Lp(a)-lowering therapies require further investigation within the evolving cardiovascular therapeutic landscape.